Roger Longman Offers Strategies to Analyze the Value of Emerging Drugs With Limited Real-World Data

Using value assessment models and data that predict real-world performance can assist in valuing drugs with limited or no real-world data, said Roger Longman, MA, chief executive officer of Real Endpoints.

Transcript

How can the US healthcare system do a better job of adequately analyzing the value of drugs, particularly new drugs that have less, or no, real-world data available?

Well, I think there are probably several ways they can do it. One is they can do a better job of more objectively measuring value and there a number of value assessment systems which have been developed including—ICER is the most obvious. The other point is that there are now contracting opportunities where you can actually go at risk for the value of a drug based on a performance. One of the things that allows you to do is to gather data on that drug through its use and ultimately use that data to either demonstrate that the clinical trials in fact predict real-world performance, or in fact, could generate other kinds of utilities for that drug that can be used then in negotiations with other payers. It’s real-world data so it’s more credible. So, these kinds of risk sharing agreements are in fact a way of creating data for drugs which don’t have the kind of data that would be required to truly judge their performance apriori.